Medicilon(SH:688202) Zheng Quan Ri Bao·2026-02-09 14:10Core Viewpoint - The company, Medici, is positioning itself as a leading Contract Research Organization (CRO) by focusing on innovative drug development technologies and enhancing its research capabilities through AI integration [2] Group 1: Innovation and Technology Development - The company is developing a three-in-one innovative technology service platform that includes human cell models, AI predictions, and organoids to enhance drug research [2] - Medici is building a one-stop preclinical research service platform based on AI technology to streamline the drug development process [2] - The company has developed an AI ADMET prediction model to improve the efficiency and success rate of drug development [2] Group 2: Collaboration and Resource Integration - Medici is collaborating with multiple AI-driven drug development companies to establish an AI drug discovery service platform, integrating external technological resources with internal research capabilities [2] - The company's AI-based one-stop preclinical research service platform project has received government approval and is already providing services to clients [2] Group 3: Competitive Advantage - The company aims to continuously enhance its research service capabilities and competitive advantages by exploring the application of relevant technologies in its research business [2]